BioMed Nexus Daily Updates

Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Friday, November 20, 2026

📌TL;DR

  • Rasonque plus chemotherapy posted a 60.7% confirmed response rate and a 12.8 month median PFS in 61 first line metastatic pancreatic cancer patients, with 76.6% alive at one year, in Revolution Medicines' open label Phase 1/2, released Thursday evening ahead of an ENA 2026 late breaking oral.

  • Celldex's barzolvolimab missed its Phase 2 atopic dermatitis primary endpoint at both doses (p=0.187 and p=0.651 against a 0.1 threshold); Celldex is discontinuing atopic dermatitis development and keeping its 2027 chronic spontaneous urticaria BLA plan.

  • Biohaven's BHV-1530 produced partial responses in 6 of 10 FGFR3 altered patients, including 3 of 3 in HPV positive head and neck cancer, with no dose limiting toxicities, per the company's release as reported by CancerNetwork.

  • The FDA approved Sanofi's Infilbray Wednesday evening as the first medicine for neurological Type 3 Gaucher disease, a week ahead of its action date and the week's fourth novel approval in three days.

  • SELLAS closed its first post pricing session at $14.86, 14.3% above the $13.00 issue price; the $150 million closing is expected Friday.

  • Tape: TEVA −8.7% first Hughes session, CAPR −6.2% into Sunday's PDUFA, XBI −0.6% against SPY −2.0%.

⚡ Executive Takeaway

Thursday was one night of answers to the same question: how narrow does biology have to be before it works? Revolution Medicines produced first line pancreatic cancer figures the field had not seen before by drugging RAS in its active state. Biohaven got responses by restricting an antibody drug conjugate to tumors carrying one altered receptor. Celldex got the opposite answer: a drug that fully suppressed its target in every patient did nothing in atopic dermatitis, because mast cells run urticaria, not eczema.

The pattern is not that precision wins; it is that unselected diseases punish even perfect target engagement. And notice what the market did with the distinction on a day the broad tape fell 2.0%: biotech barely moved. The sector is no longer trading as one bet on rates. It trades name by name, on whether each program's biology is specific enough to count.

Friday grades fast: it is the first session for both Revolution Medicines and Celldex, the SELLAS closing is due, and Capricor's action date arrives Sunday.

🧬 Rasonque Resets the First Line Pancreatic Bar

Revolution Medicines put up response and survival figures first line pancreatic cancer has not seen, and the randomized test is already enrolling. RVMD

The update from the Phase 1/2 RMC-GI-102 study, released at 6:05 pm Thursday ahead of a late breaking oral at ENA 2026 in Barcelona: 61 first line metastatic pancreatic cancer patients on Rasonque (daraxonrasib) 200 mg plus gemcitabine and nab-paclitaxel showed a 60.7% confirmed response rate with complete responses in 8.2%, disease control of 90.2%, median response duration of 11.1 months, median progression free survival of 12.8 months and 76.6% of patients alive at one year, at a median follow up of 18.3 months. Every figure is from the company's release.

The caveats are structural: open label, single arm, investigator assessed, 61 patients. The randomized answer belongs to RASolute 303, the ongoing Phase 3 testing the combination against chemotherapy alone in treatment naive patients regardless of RAS genotype, and the FDA has already granted the first line combination Breakthrough Therapy Designation. Dr. Wungki Park of Memorial Sloan Kettering, who presents the data, called the one year survival estimate meaningful. Friday is the first session to price it.

💊 A Clean No in Atopic Dermatitis

Barzolvolimab suppressed its target completely and still missed, so Celldex killed the indication the same afternoon; the urticaria franchise is untouched. CLDX

Against a 0.1 significance threshold, the 300 mg arm ran 9.7 points better than placebo on the itch endpoint's percent change at p=0.187, and the 150 mg arm finished behind placebo, in a fully enrolled 131 patient Phase 2 across 28 US centers. Secondaries did not separate, and week 32 showed no late rescue. What makes the readout clean rather than merely bad: barzolvolimab suppressed tryptase rapidly and profoundly at both doses, so the target was engaged and the biology simply is not causal in eczema; Celldex's own conclusion is that mast cells are not a primary driver of the disease. The company killed the indication the same afternoon, kept the 2027 chronic spontaneous urticaria BLA plan, kept two more Phase 3 urticaria programs enrolling, and says it will name additional indications by year end. The release crossed at 4:01 pm Thursday, one minute after the close; Friday prices it.

🔬 The ADC Without the Class Toxicities

Biohaven's FGFR3 directed ADC produced responses in biomarker selected bladder and head and neck cancers with none of the FGFR class toxicities, per the company via CancerNetwork. BHVN

Per Biohaven's Thursday release, as reported by CancerNetwork (we could not retrieve the release itself by press time), the Phase 1 study produced partial responses in 6 of 10 efficacy evaluable patients with activating FGFR3 alterations at doses of 3.3 mg/kg and up: 3 of 5 in urothelial cancer, one of them after a prior FGFR inhibitor, and 3 of 3 in HPV positive head and neck cancer, with 9 of the 10 showing tumor reductions. Across 30 treated patients there were no dose limiting toxicities and no treatment related serious adverse events, and none of the toxicities that cap FGFR small molecules: no hyperphosphatemia, no nail dystrophy, no retinopathy. Biohaven completed an FDA Type C meeting this quarter and is aiming a pivotal study in FGFR3 altered tumors, urothelial first, at the first half of 2027 with possible accelerated approval as the goal. The stock closed up 5.8% on presentation day.

🧪 Four Approvals in Three Days

The FDA approved Sanofi's Infilbray for neurological Type 3 Gaucher disease a week early, its fourth new drug of the week, while the market graded the gMG winner cautiously. SNY | REGN

Infilbray (venglustat) is the first medicine for the neurological manifestations of Type 3 Gaucher disease: a once daily oral that inhibits glucosylceramide synthase and crosses the blood brain barrier, which infused enzyme replacement cannot. In the 43 patient LEAP2MONO Phase 3 it beat imiglucerase on the combined neurological assessment at week 52 while matching it on the systemic measures. The approval crossed Wednesday evening, after Thursday's edition was built, and landed a week before its November 25 action date. Sanofi has not disclosed a US price; that watch is now open. The week's count: Klygefa Monday, neladalkib Tuesday, Livsayis and Infilbray Wednesday. The market graded the gMG winner cautiously: Regeneron's first session after Livsayis closed down 2.3% on a hard tape.

📈 The $13.00 Line Held

The first session after the $13.00 pricing closed 14.3% above issue; the book was real. SLS

We wrote Wednesday night that the $13.00 clearing price was the real grade of SELLAS's Phase 3 win, and that the first post pricing session would grade the book. It held: $14.86 at the close, 14.3% above issue, our arithmetic from settled closes, on a day the S&P fell 2.0%. A break of $13.00 would have said the book was stuffed; a 14% cushion says the buyers were real and the discount was the price of certainty, not a verdict on the asset. The $150 million closing is expected Friday; the overallotment, up to roughly $22.5 million more, is the next tell.

📊 A Hard Tape, Except in Biotech

The S&P fell 2.0% and biotech fell 0.6%; Thursday's big moves were company stories, not sector ones. TEVA | MRK | CAPR

Teva fell 8.7% in the first session after Eric Hughes's exit from the R&D chair was announced Wednesday evening; we found no new company disclosure Thursday, and the move landed on the week's softest tape, so read it as governance repricing plus beta rather than a verdict on the pipeline he presented at R&D Day eight days earlier. Merck's second session after the nemtabrutinib discontinuation took it down another 3.6%, now 7.4% across two days. Capricor slid 6.2% into Sunday's deramiocel action date. And Boston Scientific priced $3.0 billion and €4.25 billion of senior notes, per its announcement, a balance sheet sized print to read against the three segment structure it adopts in January.

📋 Quick Hits

  • Guardant Health launched Reveal Ultra, a new tier of its blood based minimal residual disease test, per the company's Thursday announcement; sensitivity claims are the company's own. GH

  • Illumina won the Virtual Cell Challenge with a model built on its billion cell atlas, per the company, a data point in the AI biology arms race among tools makers. ILMN

  • Co-Diagnostics announced a reverse stock split, the small cap diagnostics survival move of the week. CODX

  • Verified absences, scope Thursday night: no CagriSema decision (sponsor materials still December 2025 submission vintage), no 340B pilot v2 ruling (searches again served only the v1 case), no BioXcel announcement five days past its action date, no SELLAS closing release yet, no MOFCOM final export catalogue.

🗓️ What To Watch Today

  • November 20: SELLAS's $150 million offering closing is expected (SLS)

  • November 20: Rasonque's late breaking ENA oral; first reaction sessions for Revolution Medicines and Celldex (RVMD, CLDX)

  • November 22: Capricor's deramiocel action date is Sunday; early FDA action is possible any day (CAPR)

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

  • The full Rasonque endpoint table, confidence intervals included, and the caveats that matter

  • Celldex's arm by arm numbers and what tryptase suppression without efficacy means

  • BHV-1530's responses by tumor type and the path to a 2027 pivotal

  • Thursday's movers table, the Infilbray detail and a fourteen question FAQ

📋 The Week in Review

  • Monday: the ivonescimab letter and the early Imfinzi plus Padcev approval set the week's rule: counted survival decides, in both directions.

  • Tuesday: SELLAS reported a 41% death risk reduction in REGAL, closed up 156.4%, and launched a $150 million offering four hours later; neladalkib was approved ten days early.

  • Wednesday: the SELLAS offering priced at $13.00, 32.1% below Tuesday's close; Livsayis and Infilbray were approved the same evening.

  • Thursday: Regeneron's first Livsayis session closed down 2.3%; Teva fell 8.7% after its R&D chief's exit; Rasonque, BHV-1530 and the Celldex miss all landed around or after the close.

  • The through line, closed: data bought access to capital at a 32% discount, and the paper then held 14.3% above issue. The counting standard disciplines the price of money; it does not break real books.

🔒 BioMed Nexus Pro

In Today's Pro Brief...

  • 🧠 What 12.8 months in first line pancreatic cancer does to the RASolute 303 bet, and the one number that decides whether Revolution Medicines is a franchise or a story

  • 💊 The kill ledger: why Celldex's clean no is worth more than most Phase 2 wins, and how to read Teva's week through the same lens

  • 📊 Capricor weekend game theory: what the tape is pricing into Sunday's action date, and the asymmetry the calendar forces from this morning

  • 🎯 Plus the full catalyst calendar, rebuilt tonight: Friday's closings through the November 30 double PDUFA and into 2027

📊 Friday poll

Three Phase 3 winners raised this month, every one at a discount.

Reply if your answer is not on the list.